Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes

Efstratios Katsoulidis, Yongzhong Li, Patrick Yoon, Antonella Sassano, Jessica Altman, Padma Kannan-Thulasiraman, Lakshmi Balasubramanian, Simrit Parmar, John Varga, Martin S. Tallman, Amit K. Verma, Leonidas C. Platanias

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The p38 mitogen-activated protein kinase (MAPK) pathway is activated by IFNs and other cytokines to mediate signals for important cellular functions, including transcriptional regulation and apoptosis. We examined the role of the p38 pathway in the generation of the effects of myelosuppressive cytokines on human hematopoiesis. Pharmacologic inhibition of p38 using BIX-01208 resulted in reversal of IFN-, tumor necrosis factor-α (TNF-α)-, and transforming growth factor-β (TGF-β)-mediated suppression of human erythroid (blast-forming unit-erythroid) and myeloid (granulocyte-macrophage colony-forming unit) colony formation, consistent with a key role for p38 in the generation of myelosuppressive signals by different cytokines. Similarly, the myelosuppressive effects of TNF-α and TGF-β were reversed by small interfering RNAs targeting p38α expression, further establishing the requirement of this kinase in the induction of myelosuppressive responses. As TNF overproduction has been implicated in the pathophysiology of bone marrow failure states, we determined whether pharmacologic inhibition of p38 reverses the hematopoietic defects seen in bone marrows from patients with myelodysplastic syndromes (MDS) and the anemia of chronic disease. Addition of pharmacologic inhibitors of p38 on such bone marrows resulted in increased numbers of erythroid and myeloid progenitors. Similarly, inhibition of the activity of the downstream effectors of p38, MAPK activated protein kinase-2, and mitogen and stress activated kinase 1 partially restored the hematopoietic defect seen in these bone marrows. Taken altogether, our data implicate the p38 MAPK in the pathophysiology of myelodysplasias and suggest that p38 pharmacologic inhibitors may have therapeutic applications in the treatment of MDS.

Original languageEnglish (US)
Pages (from-to)9029-9037
Number of pages9
JournalCancer Research
Volume65
Issue number19
DOIs
StatePublished - Oct 1 2005
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
p38 Mitogen-Activated Protein Kinases
Bone Marrow
Cytokines
Transforming Growth Factors
Tumor Necrosis Factor-alpha
MAP Kinase Kinase 1
MAP Kinase Kinase 4
Cohort Effect
Granulocyte-Macrophage Progenitor Cells
Hematopoiesis
Small Interfering RNA
Anemia
Chronic Disease
Phosphotransferases
Apoptosis
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Katsoulidis, E., Li, Y., Yoon, P., Sassano, A., Altman, J., Kannan-Thulasiraman, P., ... Platanias, L. C. (2005). Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Research, 65(19), 9029-9037. https://doi.org/10.1158/0008-5472.CAN-04-4555

Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. / Katsoulidis, Efstratios; Li, Yongzhong; Yoon, Patrick; Sassano, Antonella; Altman, Jessica; Kannan-Thulasiraman, Padma; Balasubramanian, Lakshmi; Parmar, Simrit; Varga, John; Tallman, Martin S.; Verma, Amit K.; Platanias, Leonidas C.

In: Cancer Research, Vol. 65, No. 19, 01.10.2005, p. 9029-9037.

Research output: Contribution to journalArticle

Katsoulidis, E, Li, Y, Yoon, P, Sassano, A, Altman, J, Kannan-Thulasiraman, P, Balasubramanian, L, Parmar, S, Varga, J, Tallman, MS, Verma, AK & Platanias, LC 2005, 'Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes', Cancer Research, vol. 65, no. 19, pp. 9029-9037. https://doi.org/10.1158/0008-5472.CAN-04-4555
Katsoulidis, Efstratios ; Li, Yongzhong ; Yoon, Patrick ; Sassano, Antonella ; Altman, Jessica ; Kannan-Thulasiraman, Padma ; Balasubramanian, Lakshmi ; Parmar, Simrit ; Varga, John ; Tallman, Martin S. ; Verma, Amit K. ; Platanias, Leonidas C. / Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. In: Cancer Research. 2005 ; Vol. 65, No. 19. pp. 9029-9037.
@article{d0e7e00cb71346fb96ee5f800ea0138e,
title = "Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes",
abstract = "The p38 mitogen-activated protein kinase (MAPK) pathway is activated by IFNs and other cytokines to mediate signals for important cellular functions, including transcriptional regulation and apoptosis. We examined the role of the p38 pathway in the generation of the effects of myelosuppressive cytokines on human hematopoiesis. Pharmacologic inhibition of p38 using BIX-01208 resulted in reversal of IFN-, tumor necrosis factor-α (TNF-α)-, and transforming growth factor-β (TGF-β)-mediated suppression of human erythroid (blast-forming unit-erythroid) and myeloid (granulocyte-macrophage colony-forming unit) colony formation, consistent with a key role for p38 in the generation of myelosuppressive signals by different cytokines. Similarly, the myelosuppressive effects of TNF-α and TGF-β were reversed by small interfering RNAs targeting p38α expression, further establishing the requirement of this kinase in the induction of myelosuppressive responses. As TNF overproduction has been implicated in the pathophysiology of bone marrow failure states, we determined whether pharmacologic inhibition of p38 reverses the hematopoietic defects seen in bone marrows from patients with myelodysplastic syndromes (MDS) and the anemia of chronic disease. Addition of pharmacologic inhibitors of p38 on such bone marrows resulted in increased numbers of erythroid and myeloid progenitors. Similarly, inhibition of the activity of the downstream effectors of p38, MAPK activated protein kinase-2, and mitogen and stress activated kinase 1 partially restored the hematopoietic defect seen in these bone marrows. Taken altogether, our data implicate the p38 MAPK in the pathophysiology of myelodysplasias and suggest that p38 pharmacologic inhibitors may have therapeutic applications in the treatment of MDS.",
author = "Efstratios Katsoulidis and Yongzhong Li and Patrick Yoon and Antonella Sassano and Jessica Altman and Padma Kannan-Thulasiraman and Lakshmi Balasubramanian and Simrit Parmar and John Varga and Tallman, {Martin S.} and Verma, {Amit K.} and Platanias, {Leonidas C.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-04-4555",
language = "English (US)",
volume = "65",
pages = "9029--9037",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes

AU - Katsoulidis, Efstratios

AU - Li, Yongzhong

AU - Yoon, Patrick

AU - Sassano, Antonella

AU - Altman, Jessica

AU - Kannan-Thulasiraman, Padma

AU - Balasubramanian, Lakshmi

AU - Parmar, Simrit

AU - Varga, John

AU - Tallman, Martin S.

AU - Verma, Amit K.

AU - Platanias, Leonidas C.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The p38 mitogen-activated protein kinase (MAPK) pathway is activated by IFNs and other cytokines to mediate signals for important cellular functions, including transcriptional regulation and apoptosis. We examined the role of the p38 pathway in the generation of the effects of myelosuppressive cytokines on human hematopoiesis. Pharmacologic inhibition of p38 using BIX-01208 resulted in reversal of IFN-, tumor necrosis factor-α (TNF-α)-, and transforming growth factor-β (TGF-β)-mediated suppression of human erythroid (blast-forming unit-erythroid) and myeloid (granulocyte-macrophage colony-forming unit) colony formation, consistent with a key role for p38 in the generation of myelosuppressive signals by different cytokines. Similarly, the myelosuppressive effects of TNF-α and TGF-β were reversed by small interfering RNAs targeting p38α expression, further establishing the requirement of this kinase in the induction of myelosuppressive responses. As TNF overproduction has been implicated in the pathophysiology of bone marrow failure states, we determined whether pharmacologic inhibition of p38 reverses the hematopoietic defects seen in bone marrows from patients with myelodysplastic syndromes (MDS) and the anemia of chronic disease. Addition of pharmacologic inhibitors of p38 on such bone marrows resulted in increased numbers of erythroid and myeloid progenitors. Similarly, inhibition of the activity of the downstream effectors of p38, MAPK activated protein kinase-2, and mitogen and stress activated kinase 1 partially restored the hematopoietic defect seen in these bone marrows. Taken altogether, our data implicate the p38 MAPK in the pathophysiology of myelodysplasias and suggest that p38 pharmacologic inhibitors may have therapeutic applications in the treatment of MDS.

AB - The p38 mitogen-activated protein kinase (MAPK) pathway is activated by IFNs and other cytokines to mediate signals for important cellular functions, including transcriptional regulation and apoptosis. We examined the role of the p38 pathway in the generation of the effects of myelosuppressive cytokines on human hematopoiesis. Pharmacologic inhibition of p38 using BIX-01208 resulted in reversal of IFN-, tumor necrosis factor-α (TNF-α)-, and transforming growth factor-β (TGF-β)-mediated suppression of human erythroid (blast-forming unit-erythroid) and myeloid (granulocyte-macrophage colony-forming unit) colony formation, consistent with a key role for p38 in the generation of myelosuppressive signals by different cytokines. Similarly, the myelosuppressive effects of TNF-α and TGF-β were reversed by small interfering RNAs targeting p38α expression, further establishing the requirement of this kinase in the induction of myelosuppressive responses. As TNF overproduction has been implicated in the pathophysiology of bone marrow failure states, we determined whether pharmacologic inhibition of p38 reverses the hematopoietic defects seen in bone marrows from patients with myelodysplastic syndromes (MDS) and the anemia of chronic disease. Addition of pharmacologic inhibitors of p38 on such bone marrows resulted in increased numbers of erythroid and myeloid progenitors. Similarly, inhibition of the activity of the downstream effectors of p38, MAPK activated protein kinase-2, and mitogen and stress activated kinase 1 partially restored the hematopoietic defect seen in these bone marrows. Taken altogether, our data implicate the p38 MAPK in the pathophysiology of myelodysplasias and suggest that p38 pharmacologic inhibitors may have therapeutic applications in the treatment of MDS.

UR - http://www.scopus.com/inward/record.url?scp=25444513364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444513364&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-4555

DO - 10.1158/0008-5472.CAN-04-4555

M3 - Article

C2 - 16204077

AN - SCOPUS:25444513364

VL - 65

SP - 9029

EP - 9037

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 19

ER -